Neural stem cells derived from human midbrain organoids as a stable source for treating Parkinson's disease: Midbrain organoid-NSCs (Og-NSC) as a stable source for PD treatment

Seung Won Kim, Hye Ji Woo, Eun Hee Kim, Hyung Sun Kim, Han Na Suh, Soo hyun Kim, Jae Jin Song, Noviana Wulansari, Minji Kang, Se Young Choi, Su Jeong Choi, Won Hyuk Jang, Jungbin Lee, Ki Hean Kim, Wongyoung Lee, Sung Hyun Kim, Jinhee Yang, Jangbeen Kyung, Hyun Seob Lee, Sang Myun ParkMi Yoon Chang, Sang Hun Lee

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Successful clinical translation of stem cell-based therapy largely relies on the scalable and reproducible preparation of donor cells with potent therapeutic capacities. In this study, midbrain organoids were yielded from human pluripotent stem cells (hPSCs) to prepare cells for Parkinson's disease (PD) therapy. Neural stem/precursor cells (NSCs) isolated from midbrain organoids (Og-NSCs) expanded stably and differentiated into midbrain-type dopamine(mDA) neurons, and an unprecedentedly high proportion expressed midbrain-specific factors, with relatively low cell line and batch-to-batch variations. Single cell transcriptome analysis followed by in vitro assays indicated that the majority of cells in the Og-NSC cultures are ventral midbrain (VM)-patterned with low levels of cellular senescence/aging and mitochondrial stress, compared to those derived from 2D-culture environments. Notably, in contrast to current methods yielding mDA neurons without astrocyte differentiation, mDA neurons that differentiated from Og-NSCs were interspersed with astrocytes as in the physiologic brain environment. Thus, the Og-NSC-derived mDA neurons exhibited improved synaptic maturity, functionality, resistance to toxic insults, and faithful expressions of the midbrain-specific factors, in vitro and in vivo long after transplantation. Consequently, Og-NSC transplantation yielded potent therapeutic outcomes that are reproducible in PD model animals. Collectively, our observations demonstrate that the organoid-based method may satisfy the demands needed in the clinical setting of PD cell therapy.

Original languageEnglish
Article number102086
JournalProgress in Neurobiology
Volume204
DOIs
Publication statusPublished - Sep 2021

Keywords

  • Astrocyte
  • Cell therapy
  • Dopaminergic neuron
  • Midbrain organoid
  • Neural stem cell
  • Parkinson's disease

Fingerprint

Dive into the research topics of 'Neural stem cells derived from human midbrain organoids as a stable source for treating Parkinson's disease: Midbrain organoid-NSCs (Og-NSC) as a stable source for PD treatment'. Together they form a unique fingerprint.

Cite this